Bio-Techne Corporation announced a strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay. The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker.

Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease. Running the Simple Plex Human Phospho Tau 217 ALZpath Assay on the Ella system will enable researchers to detect the pTau217 signal in less invasive sample collection types, like plasma samples, in just 90 minutes with no manual intervention, increasing efficiency, scalability, and precision while providing the necessary data to help accelerate clinical decisions.